Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a suspected or confirmed diagnosis of a high-grade or low-grade brain tumour (glioma), or whose tumour is suspected to have a specific genetic change called an IDH mutation
- People who may be receiving radiation therapy as part of their treatment
- People who are aged 18 years or older
- People (or their guardian) who are able to give written permission to take part before the study begins
Who may not be able to join:
- People with severe claustrophobia that would prevent them from having an MRI scan
- People who are known to have had an allergic reaction to a contrast dye called Gd-DTPA (gadolinium)
- People who have any other medical reason that prevents them from receiving gadolinium contrast dye, as determined by standard radiology department guidelines
- People who have any medical device or condition that makes having an MRI scan unsafe — for example, a pacemaker, a certain type of surgical clip in the brain (aneurysm clip), or a tissue expander
- People who are pregnant or currently breastfeeding
- People who are unable to cooperate with the requirements of an MRI scan or radiation therapy planning
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Robert Young, MD, Memorial Sloan Kettering Cancer Center
Phone: 212-639-8196
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To assess the utility of baseline advanced MRI & changes between baseline & follow up advanced MRI in predicting high risk areas that are likely to develop progressive glioma despite chemoradiotherapy.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.